Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECT OF LISINOPRIL ON 24-HOUR BLOOD PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH ARTERIAL HYPERTENSION AND RHEUMATOID ARTHRITIS

https://doi.org/10.20996/1819-6446-2017-13-5-661-666

Full Text:

Abstract

Aim. To study effect of 24-week treatment with lisinopril on blood pressure (BP) and arterial stiffness in patients with arterial hypertension (HT) and rheumatoid arthritis (RA).

Material and methods. Twenty patients with essential HT grade  1-2 and RA (mean age 60.2±7.9 years) were treated with lisinoprilin 24 weeks in open controlled study. Office blood pressure (BP) was 147.2±9.4/87.5±8.6 mm Hg; 24-h mean  BP – 141.8±9.3/82.2±9.6 mm Hg; HT duration was 14.5±9.4 years, and RA duration – 12.3±2.6 years. A high incidence of traditional cardiovascular risk factors was identified: 95% of patients had dyslipidaemia, 45% – obesity, 35% – impaired glucose tolerance. Atherosclerosis of carotid arteries with stenosis less than 25% was diagnosed in 65% of patients. Most patients had a positive rheumatoid factor and cyclic citrullinated peptide antibodies, as well as moderate RA activity and III-IV radiologic stage of RA. All patients received methotrexate as the basic anti-inflammatory drug, 12 (60%) patients – selective cyclooxygenase-2 inhibitors, 6 (30%) patients took corticosteroids equivalent to prednisolone 7.5±5.5 mg per day. Mean  dose  of lisinopril was 12.2±9.8 mg/day. Office BP measurements, 24-hour ambulatory BP monitoring (ABPM), and  arterial stiffness evaluation were  performed initially and  at the end of the study. Arterial stiffness was assessed by cardio-ankle vascular index on the right (R-CAVI) and on the left (L-CAVI).

Results. After 24-week therapy with lisinopril office systolic and diastolic BP significantly decreased by 16.0±7.2/11.6±9.1 mm Hg (p<0.0001) and 11.6±9.1 mm Hg (p<0.0001), respectively. The target BP was achieved in 16 (83%) patients. According to the ABPM 24-week therapy with lisino pril led to a significant (p<0.002) decrease in BP for all referable periods: by 12.4±9.1/7.6±3.9 mm Hg within 24 hours;  by 13.4±10.1/8.0±6.1 mm Hg for daytime; by 10.1±9.3/7.3±6.3 mm Hg for night-time. After lisinopril treatment, R-CAVI decreased from 8.9±1.7 to 8.4±1.6 relative units (p=0.011), L-CAVI decreased from 8.9±1.6 to 8.4±1.5 relative units (p=0.003).

Conclusion. In patients with combination of HT and RA, 24-week therapy with lisinopril had a significant antihypertensive effect and improved the elastic properties of the vessels.

About the Authors

O. L. Sarkisova
Siberian State Medical University
Russian Federation

Olga L. Sarkisova – MD, PhD student, Chair of Faculty Therapy with Course of Clinical Pharmacology.

Moscovsky trakt 2, Tomsk, 634050



N. V. Rebrova
Siberian State Medical University; Cardiology Research Institute, Tomsk National Research Medical Centre
Russian Federation

Natalia V. Rebrova – MD, PhD, Associate Professor, Chair of Faculty Therapy with Course of Clinical Pharmacology SSMU; Researcher,  Department of Arterial Hypertensions CRI TNR MC.

Moscovsky trakt 2, Tomsk, 634050; Kievskaya ul. 111a, Tomsk, 634012



I. I. Bogomolova
Siberian State Medical University
Russian Federation

Irina I. Bogomolova – MD, Head of the Admission Department of the Clinics.

Moscovsky trakt 2, Tomsk, 634050



E. A. Anisimova
Siberian State Medical University; Cardiology Research Institute, Tomsk National Research Medical Centre
Russian Federation

Elena A., Anisimova – MD, Assistant, Center for Medical Simulation, Appraisal and Certification.

Moscovsky trakt 2, Tomsk, 634050; Kievskaya ul. 111a, Tomsk, 634012



R. S. Karpov
Siberian State Medical University; Cardiology Research Institute, Tomsk National Research Medical Centre
Russian Federation

Rostislav S., Karpov – MD, PhD, Professor, Academician of the Russian Academy of Sciences, Head of Chair of Faculty Therapy with Course of Clinical Pharmacology SSMU; Scientific Adviser on Applied Research CRI TNR MC.

Moscovsky trakt 2, Tomsk, 634050; Kievskaya ul. 111a, Tomsk, 634012



V. F. Mordovin
Cardiology Research Institute, Tomsk National Research Medical Centre
Russian Federation

Viktor F., Mordovin – MD, PhD, Professor, Head of Department of Arterial Hypertensions.

Kievskaya ul. 111a, Tomsk, 634012



T. G. Khruleva
Siberian State Medical University
Russian Federation

Tatyana G. Khruleva – MD, PhD, Associate Professor, Chair of Faculty Therapy with Course of Clinical Pharmacology  SSMU.

Moscovsky trakt 2, Tomsk, 634050



References

1. Zhugrova ES, Mazurov VI, Lila AM, et al. Dynamics of cytokine status in patients with rheumatoid arthritis on the background of the use of infliximab (Remicade). Meditsinskaja Immunologya 2008;10(2-3):251-60. (In Russ.) [ЖугроваЕ.С., МазуровВ.И., ЛилаА.М.,идр. Динамика цитокинового статуса у больных ревматоидным артритом на фоне применения инфликсимаба (ремикейда). Медицинская Иммунология. 2008;10(2-3):251-60].

2. Nasonov E.L., Karateev D.E., Satybaldiev A.M. et al. Rheumatoid arthritis in the Russian Federation according to the Russian register of patients with arthritis (report I). Nauchno-Prakticheskaya Rheumatologiya. 2015;53(5):472-84. (In Russ) [Насонов Е.Л., Каратеев Д.Е., Сатыбалдыев А.М. и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая Ревматология. 2015;53(5):472-84].

3. Goodson N.I., Willes N.J., Lunt N.C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthritis Rheum. 2002;46:2010-19. DOI:10.1136/ard.2006.056390

4. Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724-5. DOI:10.1136/ard.2007.073718

5. Novikova D.S., Popkova T.V., Mach E.S., et al. Arterial stiffness is an integral indicator of cardiovascular risk in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Rheumatologiya. 2009;5:38-47. (In Russ.) [Новикова Д.С., Попкова Т.В., МачЭ.С. и др. Ригидность артерий-интегральный показатель сердечно-сосудистого риска у больных ревматоидным артритом. Научно-практическая Ревматология. 2009;5:38-47].

6. Klocke R., Cockcroft J.R., Taylor G.J. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis. 2003;62:414-18. Doi: 10.1136/ard.62.5.414

7. Avalos I., Chung C.P., Oeser A. Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. Rheumatology. 2007;34:2388-94.

8. Rasmussen T.E., Hallett J.W., Tazelaar H.D., et al. Human leukocyteantigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aorticaneurysms. J Vasc Surg. 2002;35:988-93. doi: 10.1067/mva.2002.121753

9. Moshnina M.A. Genetics of rheumatoid arthritis. Nauchno-Prakticheskaya Rheumatologiya. 2005;4:62-8. (In Russ.) [Мошнина М.А. Генетика ревматоидного артрита. Научно-практическая Ревматология. 2005;4:62-8].

10. Turesson C., Jacobsson L., Ryde A. Increased stiffness of the abdominal aorta in women with rheumatoid arthritis. Rheumatology. 2005;44:896-901. doi: 10.1093/rheumatology/keh607

11. Zieman S.J. Mechanisms, pathophysiology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932-943. DOI: 10.1161/01.ATV.0000160548.78317.29

12. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c.

13. Karateev A.E., Nasonov E.L., Yakhno N.N. Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." Sovremennaya Rheumatologiya. 2015;9(1):4-23. (In Russ.) [Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная Ревматология. 2015;9(1):4-23].

14. Ezhov M.V. Arterial hypertension and the use of non-steroidal anti-inflammatory drugs: the benefits of amlodipine. Systemnie Hypertensii. 2009;1:23-5. (In Russ.) [Ежов М.В. Артериальная гипертония и применение нестероидных противовоспалительных препаратов: преимущества амлодипина. Системные Гипертензии. 2009;1:23-5].

15. Wbelton A., White W., Bello A.E., et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63. doi: 10.1016/S0002-9149(02)02661-9

16. Savenkov M.P., Brodskaya S.A., Ivanov S.N, Sudakova N.I. Effect of non-steroidal anti-inflammatory drugs on the antihypertensive effect of ACE inhibitors. Russkij Medicinskij Zhurnal. 2003;19:1056-9. (In Russ.) [Савенков М.П., Бродская С.А., Иванов С.Н., Судакова Н.И. Влияние нестероидных противовоспалительных средств на антигипертензивный эффект ингибиторов АПФ. Русский Медицинский Журнал. 2003;19:1056-9].

17. Maki-Petaja K., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulsewave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation. 2006;114:1184-92. DOI: 10.1161/CIRCULATIONAHA.105.601641

18. Cypiene A., Laucevicius A., Venalis A., et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNFα blocker Remicade (infliximab). Proc West Pharmacol Soc. 2007;50:119-22.

19. Nasonov EL, Karateev DE, Chichasova NE. EULAR recommendations for rheumatoid arthritis treat-ment-2013: general characteristics and disputable problems. Nauchno-Prakticheskaya Rheumatologiya. 2013;51(6):609-22. (In Russ.) [Насонов Е.Л., Каратеев Д.Е., Чичасова Н.Е. Рекомендации EULAR по лечению ревматоидног оартрита-2013: общая характеристика и дискуссионные проблемы. Научно-практическая Ревматология. 2013;51(6):609-22].

20. Tyurenkov I.N., Voronkov A.V., Sliezans A.A., Volotova E.V. Endothelial protection drugs a new class of pharmacological agents. Vestnik Rossiiskoi Akademii Meditsinskih Nauk. 2012;67(7):50-7. (In Russ.) [Тюренков И.Н., Воронков А.В., Слиецанс А.А., Волотова Е.В. Эндотелиопротекторы — новый классфармакологических препаратов. Вестник Российской Академии Медицинских Наук. 2012;67(7):50-7]. doi: 10.15690/vramn.v67i7.341

21. Flammer A.J., Sudano I., Hermann F., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008;117:2262-9. doi: 10.1161/CIRCULATIONAHA.107.734384.

22. Delpraissy S.F., Balavoine Y.F., Wallon C., Dorment J. Captopril and immune regulation. Kidney Int. 1984;25:923-9. doi: 10.1038/ki.1984.111


For citation:


Sarkisova O.L., Rebrova N.V., Bogomolova I.I., Anisimova E.A., Karpov R.S., Mordovin V.F., Khruleva T.G. EFFECT OF LISINOPRIL ON 24-HOUR BLOOD PRESSURE AND ARTERIAL STIFFNESS IN PATIENTS WITH ARTERIAL HYPERTENSION AND RHEUMATOID ARTHRITIS. Rational Pharmacotherapy in Cardiology. 2017;13(5):661-666. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-5-661-666

Views: 355


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)